top of page

U.S. FDA approves Pfizer's COVID-19 pill for prescribing

Writer: Capitol TimesCapitol Times




Pfizer Inc.'s COVID-19 pill can now be prescribed by state-licensed pharmacists, according to the US Food and Drug Administration.



There have been nearly 4 million courses of Paxlovid distributed to pharmacies in the United States so far, but fewer than half have been used so far. The drug has been cleared for use and free in the United States since December.



“Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients,” Patrizia Cavazzoni, director for the FDA’s Center for Drug Evaluation and Research, said in a statement.



Recently, however, infection rates have increased, leading to an increased use of the pill, authorized to prevent severe illness in newly infected, at-risk people.



Prescription decisions should be made by doctors whenever possible, the American Medical Association said in a statement.



“It (Paxlovid) is not for everyone and prescribing it requires knowledge of a patient’s medical history, as well as clinical monitoring for side effects and follow-up care to determine whether a patient is improving,” said AMA President Jack Resneck.



8 July 2022

Kommentare


Contact us

Letter to Editor-In-Chief
Editor@capitoltimesmedia.com

For Advertising in
Capitol Times Magazine:

ads@capitoltimesmedia.com

Capitol Times magazine Issue 5
Capitol times magazine 9
Capitol times magazine 10

Join our mailing list

FOLLOW US

  • X
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Disclaimer:

The views and opinions expressed in the articles or Interviews published in this magazine are solely those of the respective authors and do not necessarily reflect the official policy or position of the Capitol Times magazine or Capitol Times Media , its editors, or its staff. The authors are solely responsible for the content of their articles. The magazine strives to provide a platform for diverse voices and opinions, and we value the principle of free expression. The magazine assumes no responsibility or liability for any errors or omissions in the content of the articles. In no event shall the Capitol Times magazine or Capitol Times Media be liable for any special, direct, indirect, or incidental damages. Furthermore, the inclusion of advertisements or sponsored content in Capitol Times magazine does not constitute an endorsement or guarantee of the products, services, or views promoted by the advertisers. Readers are encouraged to conduct their own research and exercise caution when making decisions based on advertisements or sponsored content featured in this publication.

Thank you for reading and engaging with our publication. Your feedback is valuable to us as we continue to provide a platform for thought-provoking content and diverse perspectives.

© 2024 by Capitol Times Media LLC - Privacy Policy

bottom of page